Nebenwirkungen · Cinqaero
CINQAERO 10 mg/mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 6
HOS-132910 · Präparat HOS-097318
Anaphylactic reaction The serious adverse reaction of anaphylactic reaction was reported and considered related to reslizumab in 3 patients (0.19%) during placebo-controlled and open-label asthma studies. These reactions were observed during or within 20 minutes after completion of the reslizumab infusion and were reported as early as the second dose of reslizumab. They were fully resolved with standard treatment with no residual effect. Manifestations included skin or mucosal involvement, dyspnoea, wheezing, gastrointestinal symptoms and chills. These cases resulted in the discontinuation of treatment. Due to an overlap in signs and symptoms, it was not possible to distinguish between an anaphylactic reaction, another hypersensitivity reaction and an infusion-related reaction in all cases (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-11T17:10:00Z · SHA-256 f212e389997963271e96173c7da28e17f5a0e78b0df699519e7f56e8e9277a73 · Passage 0db6e9e52519a5a7e8ba770cd97441a08bc8072283e87e02d5e3a276adeec4be · Zeichen 1518–2337 im Abschnitt